ID

41070

Description

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01289457

Lien

https://clinicaltrials.gov/show/NCT01289457

Mots-clés

Versions (1)
  1. 19/06/2020 19/06/2020 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

19 juin 2020

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Leukemia NCT01289457

Anglais

Eligibility Leukemia NCT01289457

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01289457
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. sign an irb-approved informed consent document.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
2. age 18 to 60. patients above the age of 60 only with principal investigator (pi) approval
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
3. diagnosis of newly diagnosed aml [other than acute promyelocytic leukemia (apl)] or high-risk (intermediate-2 or high by ipss or > 10% blasts, including cmml) mds. prior therapy with hydrea and the use of a single or a two day dose of cytarabine (up to 3 g/m2) for emergency use up to 24 hours prior to start of study therapy is allowed. prior therapy for mds or other ahd is not allowed.
Description

Leukemia, Myelocytic, Acute | Exception Acute Promyelocytic Leukemia | High risk MYELODYSPLASTIC SYNDROME IPSS | Blasts Percentage | Leukemia, Myelomonocytic, Chronic | Hydrea | Cytarabine Dose U/day

Type de données

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0023487
UMLS CUI [3,1]
C4319571
UMLS CUI [3,2]
C3463824
UMLS CUI [3,3]
C2827405
UMLS CUI [4,1]
C0368761
UMLS CUI [4,2]
C0439165
UMLS CUI [5]
C0023480
UMLS CUI [6]
C0591617
UMLS CUI [7,1]
C0010711
UMLS CUI [7,2]
C0178602
UMLS CUI [7,3]
C0456683
4. ecog performance status of </= 3 at study entry.
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
5. organ function as defined below (unless due to leukemia): serum creatinine </= 3 mg/dl total bilirubin </= 2.5 mg/dl , alt (sgpt) </= 3 * uln or </= 5 * uln if related to disease.
Description

Organ function | Exception Due to Leukemia | Creatinine measurement, serum | Serum total bilirubin measurement | Alanine aminotransferase measurement | Relationship Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0023418
UMLS CUI [3]
C0201976
UMLS CUI [4]
C1278039
UMLS CUI [5]
C0201836
UMLS CUI [6,1]
C0439849
UMLS CUI [6,2]
C0012634
6. women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and must agree to practice acceptable contraceptive methods. men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.
Description

Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative | Childbearing Potential Contraceptive methods | Gender Preventing Reproduction | Gender Use of Condom | Partner Childbearing Potential

Type de données

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430061
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0430057
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C1292733
UMLS CUI [4,3]
C0035150
UMLS CUI [5,1]
C0079399
UMLS CUI [5,2]
C1524063
UMLS CUI [5,3]
C0009653
UMLS CUI [6,1]
C0682323
UMLS CUI [6,2]
C3831118
7. cardiac ejection fraction >/= 40% (by either cardiac echo or muga scan). documentation of recent (</= 6 months from screening) outside reports is acceptable.
Description

Cardiac ejection fraction Echocardiography | Cardiac ejection fraction MUGA scan

Type de données

boolean

Alias
UMLS CUI [1,1]
C0232174
UMLS CUI [1,2]
C0013516
UMLS CUI [2,1]
C0232174
UMLS CUI [2,2]
C0521317
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. breast feeding females
Description

Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0006147
2. patients with uncontrolled active infections (viral, bacterial, and fungal are not eligible).
Description

Communicable Diseases Uncontrolled | Virus Diseases | Bacterial Infections | Mycoses

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0042769
UMLS CUI [3]
C0004623
UMLS CUI [4]
C0026946
3. patients with active secondary malignancy will not be eligible.
Description

Secondary Malignant Neoplasm

Type de données

boolean

Alias
UMLS CUI [1]
C3266877
Retour au début de la page

Similar models

Eligibility Leukemia NCT01289457

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01289457
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. sign an irb-approved informed consent document.
boolean
C0021430 (UMLS CUI [1])
Age
Item
2. age 18 to 60. patients above the age of 60 only with principal investigator (pi) approval
boolean
C0001779 (UMLS CUI [1])
Leukemia, Myelocytic, Acute | Exception Acute Promyelocytic Leukemia | High risk MYELODYSPLASTIC SYNDROME IPSS | Blasts Percentage | Leukemia, Myelomonocytic, Chronic | Hydrea | Cytarabine Dose U/day
Item
3. diagnosis of newly diagnosed aml [other than acute promyelocytic leukemia (apl)] or high-risk (intermediate-2 or high by ipss or > 10% blasts, including cmml) mds. prior therapy with hydrea and the use of a single or a two day dose of cytarabine (up to 3 g/m2) for emergency use up to 24 hours prior to start of study therapy is allowed. prior therapy for mds or other ahd is not allowed.
boolean
C0023467 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0023487 (UMLS CUI [2,2])
C4319571 (UMLS CUI [3,1])
C3463824 (UMLS CUI [3,2])
C2827405 (UMLS CUI [3,3])
C0368761 (UMLS CUI [4,1])
C0439165 (UMLS CUI [4,2])
C0023480 (UMLS CUI [5])
C0591617 (UMLS CUI [6])
C0010711 (UMLS CUI [7,1])
C0178602 (UMLS CUI [7,2])
C0456683 (UMLS CUI [7,3])
ECOG performance status
Item
4. ecog performance status of </= 3 at study entry.
boolean
C1520224 (UMLS CUI [1])
Organ function | Exception Due to Leukemia | Creatinine measurement, serum | Serum total bilirubin measurement | Alanine aminotransferase measurement | Relationship Disease
Item
5. organ function as defined below (unless due to leukemia): serum creatinine </= 3 mg/dl total bilirubin </= 2.5 mg/dl , alt (sgpt) </= 3 * uln or </= 5 * uln if related to disease.
boolean
C0678852 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0023418 (UMLS CUI [2,3])
C0201976 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0439849 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative | Childbearing Potential Contraceptive methods | Gender Preventing Reproduction | Gender Use of Condom | Partner Childbearing Potential
Item
6. women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and must agree to practice acceptable contraceptive methods. men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430057 (UMLS CUI [2,2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C0079399 (UMLS CUI [4,1])
C1292733 (UMLS CUI [4,2])
C0035150 (UMLS CUI [4,3])
C0079399 (UMLS CUI [5,1])
C1524063 (UMLS CUI [5,2])
C0009653 (UMLS CUI [5,3])
C0682323 (UMLS CUI [6,1])
C3831118 (UMLS CUI [6,2])
Cardiac ejection fraction Echocardiography | Cardiac ejection fraction MUGA scan
Item
7. cardiac ejection fraction >/= 40% (by either cardiac echo or muga scan). documentation of recent (</= 6 months from screening) outside reports is acceptable.
boolean
C0232174 (UMLS CUI [1,1])
C0013516 (UMLS CUI [1,2])
C0232174 (UMLS CUI [2,1])
C0521317 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Breast Feeding
Item
1. breast feeding females
boolean
C0006147 (UMLS CUI [1])
Communicable Diseases Uncontrolled | Virus Diseases | Bacterial Infections | Mycoses
Item
2. patients with uncontrolled active infections (viral, bacterial, and fungal are not eligible).
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0042769 (UMLS CUI [2])
C0004623 (UMLS CUI [3])
C0026946 (UMLS CUI [4])
Secondary Malignant Neoplasm
Item
3. patients with active secondary malignancy will not be eligible.
boolean
C3266877 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial